Eli Lilly and Company

Eli Lilly

Zhaogen Chen

John M Schaus

Thomas Daniel Aicher

Jefferson Ray McCowan

James Lee Toth

Leonard Larry Winneroski, Jr

David Edward Tupper

Matthew Joseph Fisher

Ronald Jay Hinklin

Owen Brendan Wallace

Vincent Patrick Rocco

Bruno Giethlen

Nancy June Snyder

Shawn Christopher Miller

Michael Philip Cohen

James Ronald Gillig

Marta Maria Pineiro-Nunez

Jon Andre Erickson

Kevin Michael Ruley

Theodore Curtis Jessop

Thomas Edward Mabry

Philip Arthur Hipskind

Mark Joseph Chicarelli

John Gordon Allen

Yanping Xu

Joseph H Krushinski, Jr

Scott Eugene Conner

Margaret Mary Faul

Jeremy Schulenburg York

Dennis C Thompson

Erik James Hembre, Ii

Patrick Gianpietro Spinazze

Chafiq Hamdouchi

Yvan Le Huerou

Thomas John Bleisch

Thomas James Beauchamp

Takako Takakuwa

Gaiying Zhao

Ying Chen

Renhua Li

Gary A Hite

Ashraf Saeed

Hongqi Tian

Alexei Pavlovych Krasutsky

Maria Cristina Garcia Paredes

Jason Kenneth Myers

Fionna Mitchell Martin

Jayana Pankajkumar Lineswala

Shaojuan Jia

Yvan LeHuerou

Emanuele Sher

Bishnu Thapa

Leonard Larry Winneroski, Ii

John Mehnert Schaus

Jefferson Ray Mccowan

Gary Alan Hite

Junior Leonard Larry Winneroski

Chafiq Hamdouchi Hamdouchi

This invention provides certain piperidine compounds as ATR antagonists, e.g., compounds of formula (I):

ATR antagonists and uses thereof

The present invention provides a compound of Formula (I) wherein R is (II) or (III); or a pharmaceutically acceptable salt thereof, useful for treating psoriasis or systemic lupus erythematosus.

7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives

The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.

Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus

The present invention provides a compound of Formula I: wherein R is or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.

Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. 

Thiophene pyrazolopyrimidine compounds

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention provides compounds of formula (I), which are antagonists of the 5-HTreceptor. 

N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. 

Thiazole pyrazolopyrimidines CRF1 receptor antagonists

The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. 

Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C) alkylene or hydroxy substituted (C) alkylene; X is oxygen or sulfur; Ris hydrogen, (C) fluroalkyl, (C) cycloalkyl, or (C) alkyl, wherein the (C) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCHCHOH, or &#x2014;CN; Ris H, halogen, (C) fluoroalkyl, (C) cycloalkyl, OR, SR, NO, CN, COR, C(O)OR, CONRR, NRR, SONRR, NRCOR, NRSOR, optionally substituted aromatic, or (C) alkyl, wherein (C) alkyl is unsubstituted or substituted with a hydroxy group; Ris hydrogen (C) fluoroalkyl, (C) alkenyl, Ar, (C)alkyl-Ar, or (C) alkyl wherein (C) alkyly is unsubstituted or substituted with a phenyl; Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic, Ris hydrogen, (C) alkyl, (C) fluoroalkyl, or optionally substituted aromatic; Rand Rare independently hydrogen, (C) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Zand Zare independently selected from hydrogen, halogen, (C) alkyl, (C) fluoroalkyl, OR, SR, NO, CN, COR, CONRR, NRR, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I) 

Piperazine substituted aryl benzodiazepines

Described herein are antipyschotic compounds of formula (I) wherein,

Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders

The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HTreceptor. The present invention further provides a method of treating disorders associated with 5-HTreceptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

[object Object]

Growing community of inventors

Noblesville, IN, United States of America

Zhaogen Chen